108 related articles for article (PubMed ID: 15321029)
1. Efficacy of low concentrations of ketorolac tromethamine in animal models of ocular inflammation.
Waterbury LD; Flach AJ
J Ocul Pharmacol Ther; 2004 Aug; 20(4):345-52. PubMed ID: 15321029
[TBL] [Abstract][Full Text] [Related]
2. Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium.
Waterbury LD; Silliman D; Jolas T
Curr Med Res Opin; 2006 Jun; 22(6):1133-40. PubMed ID: 16846546
[TBL] [Abstract][Full Text] [Related]
3. Comparison of ketorolac tromethamine, diclofenac sodium, and loteprednol etabonate in an animal model of ocular inflammation.
Waterbury LD; Flach AJ
J Ocul Pharmacol Ther; 2006 Jun; 22(3):155-9. PubMed ID: 16808675
[TBL] [Abstract][Full Text] [Related]
4. Ocular penetration and anti-inflammatory activity of ketorolac 0.45% and bromfenac 0.09% against lipopolysaccharide-induced inflammation.
Waterbury LD; Galindo D; Villanueva L; Nguyen C; Patel M; Borbridge L; Attar M; Schiffman RM; Hollander DA
J Ocul Pharmacol Ther; 2011 Apr; 27(2):173-8. PubMed ID: 21351868
[TBL] [Abstract][Full Text] [Related]
5. Confocal Raman spectroscopy: Evaluation of a non-invasive technique for the detection of topically applied ketorolac tromethamine in vitro and in vivo.
Bertens CJF; Zhang S; Erckens RJ; van den Biggelaar FJHM; Berendschot TTJM; Webers CAB; Nuijts RMMA; Gijs M
Int J Pharm; 2019 Oct; 570():118641. PubMed ID: 31446026
[TBL] [Abstract][Full Text] [Related]
6. Intraocular penetration of periocular ketorolac and efficacy in experimental uveitis.
Rabiah PK; Fiscella RG; Tessler HH
Invest Ophthalmol Vis Sci; 1996 Mar; 37(4):613-8. PubMed ID: 8595961
[TBL] [Abstract][Full Text] [Related]
7. [Antiinflammatory capacity of topical ketorolac in experimental model of ocular inflammation].
Moreno OR; Andrés RC; Júlvez LP; Llorens VP; Marín Del Tiempo D; Novella EF; Torrón C; Honrubia FM
Arch Soc Esp Oftalmol; 2000; 75(5):333-8. PubMed ID: 11151171
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and efficacy of a ketorolac-loaded ocular coil in New Zealand white rabbits.
Bertens CJF; Gijs M; Dias AAJ; van den Biggelaar FJHM; Ghosh A; Sethu S; Nuijts RMMA
Drug Deliv; 2021 Dec; 28(1):400-407. PubMed ID: 33594935
[TBL] [Abstract][Full Text] [Related]
9. [Study of topical ketorolac effect on arachidonic acid metabolism in experimental anterior uveitis].
Cuevas Andrés R ; Ruiz Moreno O ; Ferrer Novella E ; Torrón Fernández-Blanco C ; Rojo Aragües A ; Pablo Júlvez LE ; Honrubia López FM
Arch Soc Esp Oftalmol; 2000 Jul; 75(7):443-8. PubMed ID: 11151195
[TBL] [Abstract][Full Text] [Related]
10. Aqueous prostaglandin E(2) of cataract patients at trough ketorolac and bromfenac levels after 2 days dosing.
Bucci FA; Waterbury LD
Adv Ther; 2009 Jun; 26(6):645-50. PubMed ID: 19568702
[TBL] [Abstract][Full Text] [Related]
11. Ocular bioavailability and tissue distribution of [14C]ketorolac tromethamine in rabbits.
Ling TL; Combs DL
J Pharm Sci; 1987 Apr; 76(4):289-94. PubMed ID: 3598886
[TBL] [Abstract][Full Text] [Related]
12. Aqueous humor penetration of ketorolac formulated in DuraSite or DuraSite 2 delivery systems compared to Acular LS in rabbits.
Shafiee A; Bowman LM; Hou E; Hosseini K
J Ocul Pharmacol Ther; 2013 Nov; 29(9):812-6. PubMed ID: 23992042
[TBL] [Abstract][Full Text] [Related]
13. Effect of benzalkonium chloride/EDTA on the ocular bioavailability of ketorolac tromethamine following ocular instillation to normal and de-epithelialized corneas of rabbits.
Madhu C; Rix PJ; Shackleton MJ; Nguyen TG; Tang-Liu DD
J Pharm Sci; 1996 Apr; 85(4):415-8. PubMed ID: 8901080
[TBL] [Abstract][Full Text] [Related]
14. The quantitative effect of 0.5% ketorolac tromethamine solution and 0.1% dexamethasone sodium phosphate solution on postsurgical blood-aqueous barrier.
Flach AJ; Kraff MC; Sanders DR; Tanenbaum L
Arch Ophthalmol; 1988 Apr; 106(4):480-3. PubMed ID: 3355415
[TBL] [Abstract][Full Text] [Related]
15. Effects of K-115, a rho-kinase inhibitor, on aqueous humor dynamics in rabbits.
Isobe T; Mizuno K; Kaneko Y; Ohta M; Koide T; Tanabe S
Curr Eye Res; 2014 Aug; 39(8):813-22. PubMed ID: 24502505
[TBL] [Abstract][Full Text] [Related]
16. An update on the use of ophthalmic ketorolac tromethamine 0.4%.
Perry HD; Donnenfeld ED
Expert Opin Pharmacother; 2006 Jan; 7(1):99-107. PubMed ID: 16370927
[TBL] [Abstract][Full Text] [Related]
17. Effects of topical ketorolac tromethamine 0.45% on intraoperative miosis and prostaglandin E
Jun JH; Yoo YS; Lim SA; Joo CK
J Cataract Refract Surg; 2017 Apr; 43(4):492-497. PubMed ID: 28532934
[TBL] [Abstract][Full Text] [Related]
18. Comparison of topical prednisolone acetate, ketorolac tromethamine and fluorometholone acetate in reducing inflammation after phacoemulsification.
Trinavarat A; Atchaneeyasakul LO; Surachatkumtonekul T; Kosrirukvongs P
J Med Assoc Thai; 2003 Feb; 86(2):143-50. PubMed ID: 12678152
[TBL] [Abstract][Full Text] [Related]
19. The analgesic and anti-inflammatory profile of ketorolac and its tromethamine salt.
Rooks WH; Maloney PJ; Shott LD; Schuler ME; Sevelius H; Strosberg AM; Tanenbaum L; Tomolonis AJ; Wallach MB; Waterbury D
Drugs Exp Clin Res; 1985; 11(8):479-92. PubMed ID: 3879752
[TBL] [Abstract][Full Text] [Related]
20. The effect of ketorolac tromethamine in reducing postoperative inflammation: double-mask parallel comparison with dexamethasone.
Flach AJ; Jaffe NS; Akers WA
Ann Ophthalmol; 1989 Nov; 21(11):407-11. PubMed ID: 2619149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
